Clinical Trial Update: Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]

View source ↗

Summary

Phase 2 long-term safety extension study update for AFQ056 in Parkinson's patients with L-dopa-induced dyskinesias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesias
• Parkinson Disease

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dyskinesias, Parkinson Disease | Phase 2 | Status: COMPLETED